The idea that GluN2D could be a viable therapeutic target is also supported by previous reports in Dlx5/6+/- mice, in which mPFC FSINs exhibited decreased functional properties that were associated with cognitive deficits in vivo, which were reversed with optogenetic stimulation of mPFC FSINs [7]. Here, DLX5 is linked to Cognitive impairment.